Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System
Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System
复制标题
DOI：
10.1016/j.jaci.2009.10.060
复制
发表时间：
2010-03-01
影响因子：
14.2
通讯作者：
Passalacqua, Giovanni
中科院分区：
文献类型：
--
作者：
Cox, Linda;Larenas-Linnemann, Desiree;Passalacqua, Giovanni
皮下变应原免疫疗法(SCIT)是治疗变应性鼻炎、哮喘和毒液过敏的有效方法，有可能导致严重的危及生命的过敏反应。不良反应一般分为两类：局部反应，可表现为注射部位的红肿、瘙痒和肿胀，以及全身反应(SRS)。SRS的严重程度从轻微的鼻炎到致命的心肺骤停不等。早期应用肾上腺素，这是治疗过敏反应的首选方法，可能会阻止SR进展为更严重的危及生命的问题。虽然关于使用肾上腺素治疗SCIT SR的争论很少，但对于何时应该第一次使用它，缺乏共识。为SCIT SRS分级的统一分类系统将有助于更准确地评估何时应使用肾上腺素。这篇文章的主要目的是讨论建议的SCIT SRS评分系统。(《过敏与免疫杂志》2010；125：569-74。)
Subcutaneous allergen immunotherapy (SCIT) is an effective treatment for allergic rhinitis, asthma and venom hypersensitivity and has the potential of producing serious life-threatening anaphylaxis. Adverse reactions are generally classified into 2 categories: local reactions, which can manifest as redness, pruritus, and swelling at the injection site, and systemic reactions (SRs). SRs can range in severity from mild rhinitis to fatal cardiopulmonary arrest. Early administration of epinephrine, which is the treatment of choice to treat anaphylaxis, may prevent the progression of an SR to a more serious life-threatening problem. Although there is little debate about using epinephrine to treat a SCIT SR, there is a, lack of consensus about when it should be first used. A uniform classification system for grading SCIT SRs will be helpful in assessing more accurately when epinephrine should be administered. The primary purpose of this article is to discuss the proposed grading system for SCIT SRs. (J Allergy Clin Immunol 2010;125:569-74.)